Compare Biogen Inc (BIIB) vs Ishares Msci Brazil ETF (EWZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Ishares Msci Brazil ETF — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Ishares Msci Brazil ETF trades at $33.85. The key difference: Biogen Inc is trading nearer its 52-week high, Ishares Msci Brazil ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | EWZ | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.63 | $41.75 |
52-Week Low | $128.93 | $27.36 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
EWZ, the iShares MSCI Brazil ETF, trades at $34.04, down 3.27% on the day. The technical outlook is bearish based on moving averages, though oscillators suggest potential for a near-term bounce. Recent news highlights institutional interest, with Empowered Funds LLC and Allspring Global Investments increasing positions in Q2 2026, while analysts debate the fund's value relative to competitors like FLBR due to its higher expense ratio.
The outlook for EWZ hinges on Brazil's economic trajectory, particularly interest rate cuts and commodity prices. Opportunities exist if Brazil's growth accelerates, but risks include U.S. tariff impacts on Brazilian exports and inconsistent dividend payouts reliant on volatile commodity stocks like Petrobras and Vale.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →
